Sec. 137308. Requirements with respect to cost-sharing for certain insulin products
426 words·~2 min read·
/bill/117/hr/5376/eh/section-137308·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Subchapter B of chapter 100 is amended by adding at the end the following new section: For plan years beginning on or after January 1, 2023, a group health plan shall provide coverage of selected insulin products, and with respect to such products, shall not— apply any deductible; or impose any cost-sharing in excess of the lesser of, per 30-day supply— $35; or the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan, including price concessions received by or on behalf of third-party entities providing services to the plan, such as pharmacy benefit management services.
In this section: The term selected insulin products means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan. The term insulin means insulin that is licensed under subsection
(a)or
(k)of section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 ( Public Law 111–148 ) and continues to be marketed pursuant to such licensure. Nothing in this section requires a plan that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan that has a network of providers from imposing higher cost-sharing than the levels specified in subsection
(a)for selected insulin products described in this section that are delivered by an out-of-network provider. Subsection
(a)shall not be construed to require coverage of, or prevent a group health plan from imposing cost-sharing other than the levels specified in subsection
(a)on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law. Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan. . The table of sections for subchapter B of chapter 100 is amended by adding at the end the following new item: Sec. 9826. Requirements with respect to cost-sharing for certain insulin products. .
Connectionstraces to 1
Traces to 1 document
1 reference not yet in our index
- Pub. L. 111-148
Citation graph
cites case law
Sec. 137308
Requirements with respect to cost-sharing for certain insulin products
Pub. L.Pub. L. 111-148
Cites 2Cited by 0 across 0 sources